Search
Tectonic Therapeutic Inc
TECXAdd to Watchlist
27.890USD
-1.910-6.41%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
526.26MMarket Cap
LossP/E TTM
More Details of Tectonic Therapeutic Inc Company
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Tectonic Therapeutic Inc Info
Ticker SymbolTECX
Company nameTectonic Therapeutic Inc
IPO dateJun 21, 2018
CEOReicin (Alise S)
Number of employees51
Security typeOrdinary Share
Fiscal year-endJun 21
Address490 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone13396663320
Websitehttps://tectonictx.com/
Ticker SymbolTECX
IPO dateJun 21, 2018
CEOReicin (Alise S)
Company Executives of Tectonic Therapeutic Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
391.06K
+19.56%
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Chief Medical Officer
Chief Medical Officer
50.39K
-2.11%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Marc Schwabish, Ph.D.
Dr. Marc Schwabish, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
391.06K
+19.56%
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Dr. Marcella Kuhlman (Marcie) Ruddy, M.D.
Chief Medical Officer
Chief Medical Officer
50.39K
-2.11%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Springer Timothy A
23.96%
Fidelity Management & Research Company LLC
14.88%
TAS Partners, L.L.C.
7.97%
TCG Crossover Management, LLC
6.20%
abrdn Inc.
6.05%
Other
40.94%
Shareholders
Shareholders
Proportion
Springer Timothy A
23.96%
Fidelity Management & Research Company LLC
14.88%
TAS Partners, L.L.C.
7.97%
TCG Crossover Management, LLC
6.20%
abrdn Inc.
6.05%
Other
40.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.96%
Individual Investor
28.00%
Hedge Fund
21.52%
Investment Advisor/Hedge Fund
14.41%
Corporation
11.45%
Private Equity
4.43%
Venture Capital
3.22%
Research Firm
1.67%
Pension Fund
0.24%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
241
15.80M
83.74%
-2.94M
2025Q4
219
13.28M
70.96%
-1.97M
2025Q3
183
12.15M
64.93%
-2.00M
2025Q2
182
18.65M
99.86%
+1.68M
2025Q1
184
18.15M
106.94%
+1.93M
2024Q4
153
13.88M
94.13%
+369.61K
2024Q3
148
13.13M
89.69%
+166.42K
2024Q2
151
11.92M
81.47%
+8.19M
2024Q1
179
2.57M
67.87%
-1.12M
2023Q4
200
2.14M
56.67%
-1.83M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Springer Timothy A
4.42M
23.55%
+196.29K
+4.64%
Apr 11, 2025
Fidelity Management & Research Company LLC
2.81M
14.95%
+661.00
+0.02%
Dec 31, 2025
TAS Partners, L.L.C.
1.38M
7.36%
+412.50K
+42.52%
Apr 03, 2025
TCG Crossover Management, LLC
1.17M
6.23%
+1.17M
--
Feb 12, 2026
abrdn Inc.
1.14M
6.08%
+785.65K
+220.58%
Dec 31, 2025
Braidwell LP
927.52K
4.94%
+190.66K
+25.87%
Dec 31, 2025
Baker Bros. Advisors LP
903.40K
4.81%
+803.40K
+803.40%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
770.07K
4.1%
+21.32K
+2.85%
Dec 31, 2025
Polaris Partners
657.98K
3.5%
-500.00K
-43.18%
Apr 03, 2025
5AM Ventures
606.66K
3.23%
+95.00K
+18.57%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.55%
ProShares Ultra Nasdaq Biotechnology
0.05%
iShares Micro-Cap ETF
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.55%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Date
Ex-dividend Date
Type
Ratio
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
